Grifols, S.A. (NASDAQ:GRFS) Sees Large Decline in Short Interest

Grifols, S.A. (NASDAQ:GRFS) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 3,130,000 shares, a drop of 10.8% from the January 15th total of 3,510,000 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average trading volume of 1,030,000 shares, the days-to-cover ratio is presently 3.0 days.

Institutional Investors Weigh In On Grifols

Hedge funds have recently bought and sold shares of the stock. R Squared Ltd purchased a new stake in shares of Grifols during the 4th quarter valued at $28,000. GAMMA Investing LLC lifted its stake in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 1,135 shares during the last quarter. Signaturefd LLC lifted its stake in Grifols by 66.2% during the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,153 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Grifols by 254.0% in the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 4,970 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Grifols by 354.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 6,335 shares during the last quarter.

Grifols Trading Up 0.8 %

Shares of GRFS traded up $0.06 during trading hours on Tuesday, reaching $7.38. 890,787 shares of the company’s stock traded hands, compared to its average volume of 787,151. Grifols has a 12 month low of $5.30 and a 12 month high of $9.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The firm’s 50 day simple moving average is $7.38 and its 200-day simple moving average is $8.09.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on GRFS shares. Morgan Stanley began coverage on shares of Grifols in a report on Wednesday, February 12th. They set an “overweight” rating on the stock. Berenberg Bank upgraded Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.